INTRODUCTION
Patient-controlled analgesia (PCA) is one of the best postoperative analgesic methods. [1] Opioids are the most common drugs used in IV pumps for pain management, but they may cause nausea/vomiting and respiratory problems. [1, 2] On the other hand, in some cases, it is diffi cult to reduce opioid doses because of the severe pain caused during the first few days. Therefore, it has been observed that adding local anesthetics, ketamine, adrenergic alpha-2 agonists, antihistamines, and nonsteroidal anti-infl ammatory drugs to opioids in PCA to enhance the quality and length of analgesia and sedation reduces the opioid doses needed and its side eff ects, including nausea/vomiting and itching. [2] Lidocaine, a local anesthetic which inhibits sodium channels, has anesthetic and analgesic eff ects when injected locally or intravenously. It has been shown that intravenous lidocaine injection can reduce postoperative pain and opiate consumption, and 60 patients with American Anesthesiology Score (ASA) I and II, candidates for orthopedic tibia open reduction internal fi xation (ORIF) surgery (between November 2008 and August 2009), were enrolled in this doubleblinded clinical trial a er they were informed of the study method and their wri en consent was obtained. The patients were divided into three equal groups through simple random sampling. The exclusion criteria were: patients with a history of epilepsy, diabetes, kidney diseases, hypertension, heart block, or addiction to drugs, severely obese patients, and patients with a medical history showing allergy to lidocaine and opioids. General anesthesia method was the same in all patients. A er performing complete monitoring (ECG, pulse oximetry, blood pressure, and ETCO2) and preoxygenation and premedication with midazolam and fentanyl, induction was made by injection of propofol plus cisatracurium. After intubation, anesthesia was maintained with propofol infusion. A er undergoing surgery and gaining complete consciousness, the patients were transferred to a ward and were included in this study for a maximum of 4 h a er surgery. Postoperative analgesia was maintained with lidocaine (Lignodic 1%; Caspian, Rasht, Iran) using 100 ml intravenous infusion pumps at a dosage of 0.8 mg/ kg/h with 4-6 ml/h fl ow rate [3] [4] [5] [6] [7] The pump solution in the fi rst group contained lidocaine 1% plus 20 mg morphine (Darupakhsh, Tehran, Iran) (LM20), in the second group contained lidocaine 1% plus 10 mg morphine (LM10), and in the third group (the control group) contained only 20 mg morphine (M20). The patients were randomly assigned to receive one of these pumps. The lockout interval was fi xed as 15 min. The researcher was not aware of the contents of the pumps, as another colleague prepared them. Patients were monitored every 12 h for 48 h to check for their Visual Analog Scale (VAS)/ Verbal Rating Scale (VRS), extra opioid doses, nausea/ vomiting, sedation score, satisfaction score (excellent, good, average, dissatisfied), [3, 4, 6, 7] and demographic scores, which were recorded in their questionnaires by a colleague who was not aware of the study group. The defi nitions of the measured items are as follows:
Visual analog scale (VAS)
On a ruler scale from 0 to 10: 0 = no pain, 10 = most severe pain imaginable.
Verbal rating scale (VRS) 1 = No pain; 2 = mild pain; 3 = average pain; 4 = severe pain Sedation score 0 = Restless; 1 = calm; 2 = sleepy; 3 = confused but responds to verbal instructions; 4 = no response to verbal instructions; 5 = no response to painful stimulations. Nausea/vomiting score 1 = No vomiting/nausea; 2 = mild nausea/vomiting with no need for medicine; 3 = nausea and need for medicine; 4 = no response to a dose of anti-nausea medicine.
Satisfaction score 1 = Excellent; 2 = good; 3 = average; 4 = dissatisfi ed.
In the event that patients experienced side eff ects or did not achieve pain control (VAS ≥ 4 and average or high VRS), the content of the pump and dosage were changed as follows:
• VAS > 4: Increased lidocaine by 20% and administered 2 mg morphine IV injection • Only nausea: Administered metoclopramide 10 mg IV injection • Any symptoms of lidocaine poisoning: Stopped the pump
In case VAS was <1 or there was mild VRS at 48 h a er PCA, lidocaine dose was cut by 50% every 12 h and then stopped. Additionally, the patients were checked for probable side eff ects like drowsiness, giddiness, and lip tingling.
In order to evaluate the gathered statistical data, SPSS 11.5 so ware was used. One-way analysis of variance (ANOVA) and Friedman and Duncan test were utilized to examine VAS/VRS, chi-square test was used for checking nausea/ vomiting, and Hawke post-test was used to evaluate how much extra opioid was needed and the total opioid used.
RESULTS
Sixty patients who were candidates for lower extremity orthopedic surgery entered this study. The fl ow diagram is given in Figure 1 . The diff erence among the three groups' demographic data (age, sex, weight, height, operation duration, ASA) was not statistically signifi cant [ Table 1 ].
Principal fi ndings of the study in both groups included the scores of pain, sedation, average morphine dose, and satisfaction [ Table 2 ].
Mean VAS/VRS scores using one-way ANOVA and Duncan tests were signifi cantly lower in the fi rst group (LM20) compared to the other two groups on the fi rst day (P < 0.01 and <0.05, respectively).
On the second day, these test results displayed lower mean VAS/VRS scores in the fi rst group (LM20) compared to the other two and the diff erence was statistically signifi cant (P < 0.01 and <0.05, respectively).
The fi gure for the number of patients in need of extra opioid was 10% in the fi rst group, 30% in the second group, and 25% in the third group. Chi-square test results displayed a statistically signifi cant diff erence (P < 0.01). Hawke post-test showed a statistically signifi cant diff erence between the fi rst group and the other two groups concerning the amount of morphine used (P < 0.01).
Although the extra morphine dose that was administered was larger in the second group (LM10) than in the other two groups, the total morphine dose used (average total morphine in the pump and extra morphine administered) was noticeably less in the second group than in the other two.
The side effects are listed in Table 3 and there was no statistically significant difference among the three groups (P > 0.1).
Sedation scores on 2 days were measured. On the fi rst day, the number of patients with sedation score ≥2 (≥median) was 3, 9, and 7 in the three groups, respectively, and on the second day, the number was 2, 8, and 6, respectively. There were no diff erences in between the groups as measured by median test (P = 0.116, P = 0.092).
Satisfaction score was measured by chi-square test and was signifi cantly be er in the fi rst group on the second day (P = 0.004).
Nausea/vomiting scores were measured and compared between groups by chi-square test, and no significant diff erence was between them (P = 0.366, P = 0.402).
DISCUSSION
Studies show that lidocaine can be eff ective in managing pain by blocking the sodium channels and possibly by having an inhibiting eff ect on N-methyl--aspartate (NMDA) receptors and protein G receptors because it can control the spontaneous impulses of pain in the posterior horn of the spinal cord and injured peripheral nerves. On the other hand, it controls aff erent synapses in the transmission path, which also aff ects the posterior horn of the spinal cord. [7] [8] [9] [10] Lidocaine causes the selective a enuation of C fi bers in the posterior column of the spiral cord, and thus can be eff ective in controlling the pain pathway. [10] The spura spinal analgesic mechanism of lidocaine is due to the changes brought about in the structure of the anterior brain, especially in cingulate cortex. [11] [12] [13] In 1992, Marche ini et al. discussed the analgesic eff ect of lidocaine infusion in controlling and relieving neuropathic pain, mechanical hyperalgesia, and postherpetic neuralgia a er herpes. [14] In Rathmell and Ballantyne's extensive metaanalysis in 2005, the eff ects of the systematic use of lidocaine in controlling neuropathic pain were examined and it was noted that lidocaine was more effective in controlling spontaneous responses than stimulated responses. [15] Schwartzman et al. examined the effect of five daily infusions of lidocaine in patients suff ering from severe complex regional pain syndrome and noted that the injection reduced mechanical and thermal sensitivity to pain in these patients. [16] Yardeni et al. studied the eff ect of lidocaine infusion before the operation on controlling the production of infl ammatory mediators like interleukin-1 and -6 and the surgery-induced immune alterations. They found that the lidocaine infusion controlled the infl ammatory responses considerably and reduced the postoperative infl ammation. [17, 18] In the study conducted by Thomas et al. , it was found that intravenous lidocaine can have a remarkable eff ect on the phantom pain and opioid-resistant pain. [19] Results from our study show that adding lidocaine 1% to 20 mg morphine in the IV PCA a er orthopedic surgery reduced the pain score without causing side eff ects. This pain-reducing response to lidocaine in our study and other studies can be a guide for treatment with Oralsodium channel blocking agents, such as Mexiletine, Gabapentin, or Duloxetine (antidepressant). [7, 13, 15, 20, 21] Opioids are the most common drugs used in patientcontrolled intravenous analgesia pumps (PCIA), but there has always been a concern about their overdose and side eff ects. This is the reason why lidocaine was examined in this study as an auxiliary medicine to morphine in PCIA, and its probable capacity for decreasing the need for opioids was tested. According to the fi ndings of our current study, adding lidocaine 1% (50 mg/h) to morphine infusion of 1 mg/h not only relieved pain and reduced the need for extra opioid doses, but also enhanced satisfaction without any side eff ects. However, adding lidocaine to morphine infusion of 0.5 mg/h was not noticeably successful. Taking into account the lack of any side eff ects resulting from lidocaine poisoning in these patients, it appears that lidocaine 1% at the mentioned infusion rate leads to no considerable side eff ects.
In a study by Gagnon et al. on patients suff ering from spinal chord injuries with severe neuropathic pain, it was noted that lidocaine infusion at less than 50 mg/h (similar to the concentration in our study) did not have any notable eff ects on these patients' pain control and hyperalgesia. [22] This does not agree with the fi ndings of our study. The discrepancy may originate from the fact that in our study, acute pain has been dealt with.
In another study on patients suffering from neuralgia a er herpes, lidocaine infusion of 50 mg/h resulted in pain control and less sensitivity to mechanical stimulation. The eff ects can even be compared to higher than 100 mg/h infusions of lidocaine. [23] These fi ndings agree with the results of the fi rst group (LM20) in our study. In Clarke et al.'s study, more than 200 mg/h infusion of lidocaine was used to control postoperative pain. It was noticed that this quantity can eff ectively control moderate and severe pain without causing side eff ects. Additionally, shorter hospitalization time of the group under study compared to the control group was one of the advantages of this method, which was economically considerable. [24] In a study by A al et al., lidocaine at a dose of 5 mg/kg/h controlled mechanical allodynia a er brain strokes in central pain syndrome. [25] In the patients suffering from neuropathic pain, lidocaine infusion at 1 mg/kg/h was used, while the serum lidocaine levels were checked every 8 h. Then lidocaine concentration was increased in a way that its plasma concentration was kept below 8 μg/ml. [26] The fi ndings of the mentioned study show that this quantity was eff ective in controlling pain. Of course, it must be noted that lidocaine has an active metabolite named monoethylglycinexylidide, which plays a role in lidocaine poisoning and anesthesia, but cannot be measured when serum lidocaine levels are checked. This raises the question of using high quantities of lidocaine.
The work of other researchers shows that lidocaine (with plasma concentrations of 5-15 μg/ml) is safe and eff ective in controlling pain. Despite many meta-analyses carried out so far, there are many issues surrounding safe and eff ective intravenous lidocaine doses, all of which need more investigation. On the other hand, there are opposing views on the maximum allowed time for lidocaine infusion and a fi nal agreement is still to be reached. [25, 26] Recently, more investigations have been done on the perioperative use of lidocaine, which have shown positive eff ects in terms of be er pain control and functional recovery and less opioid consumption. [27] [28] [29] [30] [31] In Schwartzman et al.'s study, lidocaine at 5 μg/ml plasma concentration was examined for 5 days to control Complex Regional Pain Syndromepain and no side eff ects were observed. [16] In conclusion, it seems that adding lidocaine to morphine in PCIA (when proper morphine concentration is chosen) can be a safe method with fewer complications in controlling postoperative pain and it can reduce the need for extra opioid doses.
Limitations of the study
Since there is no contentious agreement on the dose of lidocaine and its infusion standards, more research regarding higher concentrations and longer duration of lidocaine infusion should be carried out. Additionally, it is recommended that the anti-infl ammatory eff ects of lidocaine be examined in future studies.
